Applied Genetic Technologies Corporation (AGTC)’s Financial Results Comparing With Biogen Inc. (NASDAQ:BIIB)

Both Applied Genetic Technologies Corporation (NASDAQ:AGTC) and Biogen Inc. (NASDAQ:BIIB) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Applied Genetic Technologies Corporation 28.99M 2.11 17.69M -1.08 0.00
Biogen Inc. 13.45B 4.70 4.43B 21.02 15.20

Table 1 showcases the gross revenue, earnings per share and valuation of Applied Genetic Technologies Corporation and Biogen Inc.


Table 2 shows us Applied Genetic Technologies Corporation and Biogen Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Applied Genetic Technologies Corporation -61.02% -19% -15.2%
Biogen Inc. 32.94% 24.2% 12.9%

Volatility & Risk

A beta of 2.01 shows that Applied Genetic Technologies Corporation is 101.00% more volatile than Standard & Poor’s 500. Biogen Inc. has a 0.98 beta and it is 2.00% less volatile than Standard & Poor’s 500.


The Current Ratio and a Quick Ratio of Applied Genetic Technologies Corporation are 4.3 and 4.3. Competitively, Biogen Inc. has 2.7 and 2.5 for Current and Quick Ratio. Applied Genetic Technologies Corporation’s better ability to pay short and long-term obligations than Biogen Inc.

Analyst Recommendations

The Recommendations and Ratings for Applied Genetic Technologies Corporation and Biogen Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Applied Genetic Technologies Corporation 0 2 1 2.33
Biogen Inc. 0 1 4 2.80

Applied Genetic Technologies Corporation has a 58.16% upside potential and an average target price of $5.33. Competitively Biogen Inc. has an average target price of $399.75, with potential upside of 24.32%. Based on the data shown earlier, Applied Genetic Technologies Corporation is looking more favorable than Biogen Inc., analysts opinion.

Insider & Institutional Ownership

Roughly 46.9% of Applied Genetic Technologies Corporation shares are held by institutional investors while 91.1% of Biogen Inc. are owned by institutional investors. About 0.3% of Applied Genetic Technologies Corporation’s share are held by insiders. Comparatively, Biogen Inc. has 0.1% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Applied Genetic Technologies Corporation -4.93% -9.26% 43.49% 35.6% 60.26% 71.39%
Biogen Inc. -4.28% -3.64% -6.12% 4.16% -0.04% 0.27%

For the past year Applied Genetic Technologies Corporation’s stock price has bigger growth than Biogen Inc.


Biogen Inc. beats Applied Genetic Technologies Corporation on 10 of the 13 factors.

Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. The companyÂ’s Phase III clinical trial products comprise GAZYVA for the treatment of front-line indolent non-hodgkinÂ’s lymphoma; and Aducanumab and E2609 for AlzheimerÂ’s disease. Its Phase II clinical trial products include BIIB074 for trigeminal neuralgia, lumbosacral radiculopathy, and erythromelalgia; BAN2401 for Alzheimer's disease; Opicinumab (anti-LINGO-1) for MS; TYSABRI for acute ischemic stroke; rAAV-XLRS for X-linked juvenile retinoschisis; BG00011 (STX-100) for idiopathic pulmonary fibrosis; and Dapirolizumab pegol and BIIB059 (Anti-BDCA02) for lupus. The companyÂ’s Phase I clinical trial products comprise BIIB061 for MS; BIIB054 for Parkinson's disease; BIIB067 (IONIS-SOD1Rx) for amyotrophic lateral sclerosis; and BIIB068 (BTK Inhibitor) for autoimmune disease. It has collaboration agreements with AbbVie, Inc.; Acorda Therapeutics, Inc.; Applied Genetic Technologies Corporation; Eisai Co., Ltd.; Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and University of Pennsylvania. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.